Perspective Confidentiality Disclosure Reliability Courtesy
Today I operated on my friend Terry. I called this evening at 9:00 to see how he was. It isn’t that I didn’t see him on rounds. It’s that he’s Terry, my friend, so I called.
I don’t often call my patients at night. There really is no good reason. This may not be the case [...]
Filed under: Management | No Comments »
In another severe setback for the application of immunotherapy in the treatment of advanced prostate cancer, Cell Genenesys has announced the early termination of the Phase III VITAL-2 clinical trial comparing GVAX + docetaxel to docetaxel + prednisone.
Filed under: Drugs in development, Treatment | Tagged: prostate, cancer, update, news, GVAX | 2 Comments »
ImClone Systems has announced the initiation of enrollment of patients with androgen-independent prostate cancer (AIPC) in a Phase II clinical trial with either IMC-A12 or IMC-1121B plus mitoxantrone and prednisone.
Filed under: Drugs in development, Management, Treatment | Tagged: prostate, cancer, update, news, IMC-A12, IMC-1121B | No Comments »
The Washington Post today published an opinion piece by William Catalona, MD strongly criticizing the recent update to the US Preventive Services Task Force’s guidelines on screening for prostate cancer.
Filed under: Diagnosis | Tagged: Catalona, guidelines, USPSTF | No Comments »
There are several interesting news items today, as follows:
Ethnic variation in the performance of PSA and PSA density as markers for risk of prostate cancer
Potential underuse of active surveillance in eligible patients
Application of active surveillance in a 40-patient case series
The potential to eliminate the need for a urethral (Foley) catheter post-surgery
Circulating tumor cell levels as [...]
Filed under: Diagnosis, Management, Treatment, Uncategorized | Tagged: prostate, cancer, PSA, deprivation, update, news, androgen, race, ethnicity, density, active, surveillance, catheter, CTC | 1 Comment »
A recent epidemiologic study in King County, Washington, has found an increased risk for prostate cancer associated with statin use among obese men.
Filed under: Prevention | Tagged: prostate, cancer, update, news, obesity, statin | No Comments »
Two reports just published would appear to confirm individual patient experiences in the treatment of advanced disease:
The impact of ADT on body composition
The effects of docetaxel chemotherapy in men aged ≥ 75 years
Filed under: Management, Treatment | Tagged: prostate, cancer, deprivation, update, news, androgen, docetaxel, chemotherapy | No Comments »
Todays’ reports contain some interesting data, although it is not entirely clear how they should best be applied in the diagnosis and potential management of patients at risk:
A study of patient preferences and decision making about how to be treated
Why some Brazilian men reject digital rectal examination (fewer that you might expect)
The natural history of [...]
Filed under: Diagnosis, Management | Tagged: prostate, cancer, update, news, preferences, DRE, ferumoxtran-10, Combidex, HGPIN | 3 Comments »
OncoGenex Pharmaceuticals announced today that OGX-011 (custirsen sodium) received Fast Track designation from the U.S. Food & Drug Administration in combination with docetaxel for potential treatment of progressive metastatic prostate cancer. OGX-011 is currently completing Phase II clinical studies in prostate and other cancers. The drug is designed to inhibit the production of a specific [...]
Filed under: Drugs in development, Treatment | No Comments »
Today’s news seems to be light and (with one exception) somewhat technical in nature:
Impact of measures of metabolic syndrome and other factors on PSA levels in healthy Korean men
A new imaging system that may be able to assist surgeons in ensuring the removal of all cancer tissue
A mathematical model for prediction of tumor size based [...]
Filed under: Diagnosis, Management, Treatment | No Comments »
